Friend leukemia integration 1 transcription factor (FLI1) (FLI1)

Friend leukemia integration 1 (Fli-1) is a member of the ETS family of transcription factors that serves as a master regulator of hematopoiesis and vasculogenesis [1, 6]. In healthy tissues, it is primarily expressed in hematopoietic stem cells and endothelial cells, where it orchestrates the development of erythroid and megakaryocytic lineages [3, 6]. Fli-1 is clinically significant as the primary fusion partner with the EWSR1 gene in approximately 85% of Ewing sarcoma cases, resulting in the oncogenic EWSR1-FLI1 fusion protein [11, 14]. Beyond pediatric bone tumors, aberrant Fli-1 expression is implicated in several leukemias and autoimmune conditions, such as systemic lupus erythematosus and systemic sclerosis [1, 9]. Therapeutic development focuses on small molecules that disrupt the protein's interaction with critical co-factors like RNA helicase A or its direct binding to DNA [9, 13]. However, drug development remains challenging due to the protein's essential role in maintaining normal blood cell production and vascular stability [3, 11].

Other names

Friend leukemia virus integration 1Proto-oncogene Fli-1Transcription factor ERGBEWSR2SIC-1BDPLT21

Inhibition of DNA binding, disruption of protein-protein interactions (such as with RNA helicase A), inhibition of transcription and translation, and induction of protein degradation [6, 9, 12, 13].